Oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues

• US 10,640,748 B2
• Filed: 12/24/2015
• Issued: 05/05/2020
• Est. Priority Date: 12/24/2014
• Status: Active Grant

• Current Assignee: Neuorphan Pty, Ltd.
• Original Assignee: Neuorphan Pty, Ltd.
• Inventors: Petratos, Steven, Azari, Michael Farzad, Lee, Jae Young, Kim, Min Joung
• Primary Examiner(s): Noble, Marcia S
• Application Number:
  US15/538,150
• Publication Number:
  US 20170342380A1
• Time in Patent Office: 1,594 Days
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: C12N 2501/395 Thyroid hormones
• CPC Class Codes: C12N 2502/081 neurons
• CPC Class Codes: C12N 2502/086 glial cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0618 Cells of the nervous system
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Abstract

The present invention relates to methods of treating or ameliorating certain neurodegenerative disorders (namely, dysmyelinating and demyelinating disorders) in patients in need of such treatment or amelioration. The invention provides methods of treating or ameliorating a patient in need of such treatment and includes the administration to the patient of: (a) thyroid hormones or thyroid hormone analogues; (b) cell replacement therapies involving the use of homogenous Oligodendrocyte Precursor Cells derived from embryonic stem cells that have been treated with thyroid hormones or thyroid hormone analogues; (c) gene therapy to correct mutated genes in vivo; or (d) a combination of two or more of (a), (b) and (c). The invention also provides compositions and formulations of thyroid hormones and thyroid hormone analogues for use in treating or ameliorating such disorders.

Claims

1. A method of differentiating a mammalian oligodendrocyte precursor cell into a mammalian oligodendrocyte, the method comprising culturing the mammalian oligodendrocyte precursor cell in a culture medium comprising 3,5-diiodothyropropionic acid (DITPA) at a concentration which is effective to cause the mammalian oligodendrocyte precursor cell to differentiate into a mammalian oligodendrocyte, wherein the mammalian oligodendrocyte precursor cell was obtained through differentiation from a mammalian embryonic stem cell.

2. The method of claim 1, wherein the mammalian embryonic stem cell is human.

3. The method of claim 1 wherein the mammalian embryonic stem cell is a human embryonic stem cell comprising a transgene encoding a green fluorescent protein (GFP) operably linked to a Nkx2.1 promoter or a HES3 reporter cell comprising a transgene encoding a GFP.

4. The method of claim 1 wherein the mammalian embryonic stem cell is an H9 human embryonic stem cell.

5. The method of claim 1, wherein the mammalian oligodendrocyte is capable of myelinating a neuron in a human subject.

6. The method of claim 1, wherein the culture medium comprises between 1 ng/mL and 100 ng/mL DITPA.

7. The method of claim 1, further comprising differentiating mammalian embryonic stem cells to obtain the mammalian oligodendrocyte precursor cell, the method comprising:

(i) culturing the mammalian embryonic stem cells in the presence of FGF2 so that a three-dimensional mass of cells form;

(ii) culturing the three-dimensional mass of cells in the presence of FGF2, FGF4, and noggin so that an embryoid body forms;

(iii) culturing the embryoid body in the presence of sonic hedgehog (shh) and FGF2 so that neural precursor cells form from cells of the embryoid body;

(iv) adding EGF to the culture of (iii) so that glial precursor cells form from the neural precursor cells; and

(v) adding PDFG to the culture of (iv) so that oligodendrocyte precursor cells form from the glial precursor cells;

wherein the culturing of the oligodendrocyte precursor cells in the medium comprising DITPA forms an oligodendrocyte that is a post-mitotic oligodendrocyte capable of myelination.

8. The method of claim 7, wherein the mammalian embryonic stem cell is a human embryonic stem cell comprising a transgene encoding a GFP operably linked to a Nkx2.1 promoter or a HES3 reporter cell comprising a transgene encoding a GFP.

9. A human oligodendrocyte precursor cell in a culture medium comprising DITPA at a concentration which is effective to cause the human oligodendrocyte precursor cell to differentiate into a human oligodendrocyte, wherein the human oligodendrocyte precursor cell was obtained through differentiation of a human embryonic stem cell and the human embryonic stem cell is a human embryonic stem cell comprising a transgene encoding GFP operably linked to a Nkx2.1 promoter or a HES3 reporter cell comprising a transgene encoding a GFP.

10. A cell line comprising a human oligodendrocyte precursor cell in a culture medium comprising DITPA at a concentration which is effective to cause the human oligodendrocyte precursor cell to differentiate into a human oligodendrocyte, wherein the human oligodendrocyte precursor cell was obtained through differentiation of a human embryonic stem cell and the human embryonic stem cell is a human embryonic stem cell comprising a transgene encoding GFP operably linked to a Nkx2.1 promoter or a HES3 reporter cell comprising a transgene encoding a GFP.